Last reviewed · How we verify

Ipratropium Bromide HFA Inhalation Aerosol — Competitive Intelligence Brief

Ipratropium Bromide HFA Inhalation Aerosol (Ipratropium Bromide HFA Inhalation Aerosol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Respiratory.

phase 2 Anticholinergic Muscarinic acetylcholine receptors Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ipratropium Bromide HFA Inhalation Aerosol (Ipratropium Bromide HFA Inhalation Aerosol) — Pearl Therapeutics, Inc.. Anticholinergic agent that inhibits muscarinic acetylcholine receptors

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ipratropium Bromide HFA Inhalation Aerosol TARGET Ipratropium Bromide HFA Inhalation Aerosol Pearl Therapeutics, Inc. phase 2 Anticholinergic Muscarinic acetylcholine receptors
SCOPOLAMINE SCOPOLAMINE marketed Anticholinergic [EPC] Muscarinic acetylcholine receptors 1979-01-01
Enlon-Plus Atropine Sulfate Alcon Labs Inc marketed Antimuscarinic agent Muscarinic acetylcholine receptors 1960-01-01
IV Neostigmine Methylsulfate + Atropine Sulphate IV Neostigmine Methylsulfate + Atropine Sulphate Damanhour Teaching Hospital marketed Acetylcholinesterase inhibitor + Antimuscarinic Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Neostigmine+Glycopyrronium Neostigmine+Glycopyrronium Pusan National University Yangsan Hospital marketed Acetylcholinesterase inhibitor + Anticholinergic agent Acetylcholinesterase; Muscarinic acetylcholine receptors
Active B&O suppository of belladonna Active B&O suppository of belladonna Edgar LeClaire, MD marketed Anticholinergic agent Muscarinic acetylcholine receptors (M1-M5)
Atropine Sulfate 0.04% Eye Drop Atropine Sulfate 0.04% Eye Drop Shanghai Eye Disease Prevention and Treatment Center marketed Anticholinergic agent / Muscarinic receptor antagonist Muscarinic acetylcholine receptors (M1, M3, M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ipratropium Bromide HFA Inhalation Aerosol — Competitive Intelligence Brief. https://druglandscape.com/ci/ipratropium-bromide-hfa-inhalation-aerosol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: